Roivant said Tuesday an experimental drug for a type of pulmonary hypertension achieved the goals of a mid-stage study — positive results that could open up a new way to treat the serious lung disease and bolster the biotech company’s financial health with a second blockbuster medicine.
In the 16-week Phase 2 study, Roivant said, its drug mosliciguat achieved a statistically significant 56% reduction compared to placebo in pulmonary vascular resistance — a measure of blood pressure and flow within the artery that connects the right side of the heart to the lungs.
Key 16-week secondary endpoints of the study were also met with statistical significance. Mosliciguat showed a 35-meter, placebo-adjusted improvement in six-minute walk distance and a 53% placebo-adjusted reduction in NT-proBNP, a blood-based marker of heart failure.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
